Panama already has the drugs Molnupiravir and Paxlovid, which seek to reduce the effects of Covid-19 in patients with chronic diseases.
Dr. Sharomay Osman, medical director of the Figali Center, explained that Paxlovid is an oral drug that is indicated for the early phase of the disease.
“It has the ability to reduce the viral load in patients, therefore delaying or reducing or mitigating the possibility of the disease progressing to more advanced stages and helps reduce symptoms,” he said.
He added that it is indicated for patients at risk: those over 50 years of age, diseases such as hypertension, diabetes, cardiovascular diseases, immunosuppressed patients, patients with mental and mood disorders, obesity, cerebral palsy, etc.
Osman said that Paxlovid is applied in the first five days of the illness, when the patient begins to have symptoms of Covid-19.
